S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

$0.82
-0.03 (-3.52%)
(As of 03/28/2024 ET)
Today's Range
$0.82
$0.85
50-Day Range
$0.28
$0.90
52-Week Range
$0.25
$1.50
Volume
10,935 shs
Average Volume
145,830 shs
Market Capitalization
$26.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Orgenesis MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.49
Upright™ Environmental Score
News Sentiment
0.43mentions of Orgenesis in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$29,483 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.12 out of 5 stars

Medical Sector

848th out of 938 stocks

Pharmaceutical Preparations Industry

385th out of 424 stocks

ORGS stock logo

About Orgenesis Stock (NASDAQ:ORGS)

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

ORGS Stock Price History

ORGS Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Orgenesis Inc. (ORGS)
Orgenesis Inc ORGS
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Orgenesis Announces Proposed Underwritten Public Offering
Orgenesis (ORGS): A Value Trap in Disguise?
See More Headlines
Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORGS
Fax
N/A
Employees
167
Year Founded
2008

Profitability

Net Income
$-14,890,000.00
Pretax Margin
-75.89%

Debt

Sales & Book Value

Annual Sales
$27.75 million
Book Value
$1.14 per share

Miscellaneous

Free Float
29,601,000
Market Cap
$26.20 million
Optionable
Optionable
Beta
1.04

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Vered Caplan M.Sc. (Age 55)
    Chairperson of the Board, CEO & President
    Comp: $335.97k
  • Prof. Sarah Ferber Ph.D. (Age 70)
    Founder & Chief Scientific Officer
    Comp: $268.32k
  • Mr. Victor Miller (Age 54)
    Chief Financial Officer
  • Pierre Lammeretz
    Interim Chief Operating Officer
  • Dr. Shimon Hassin Ph.D.
    Chief Technology Officer
  • Mr. Evan Fishman
    Chief Financial Officer of Orgenesis Biotech
  • Mr. Joseph Carpinelli
    Chief Financial Officer of Octomera

ORGS Stock Analysis - Frequently Asked Questions

How have ORGS shares performed in 2024?

Orgenesis' stock was trading at $0.5007 on January 1st, 2024. Since then, ORGS shares have increased by 64.2% and is now trading at $0.8220.
View the best growth stocks for 2024 here
.

Are investors shorting Orgenesis?

Orgenesis saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 322,200 shares, an increase of 42.8% from the February 29th total of 225,700 shares. Based on an average daily trading volume, of 146,200 shares, the days-to-cover ratio is currently 2.2 days.
View Orgenesis' Short Interest
.

When is Orgenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our ORGS earnings forecast
.

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NASDAQ:ORGS) issued its earnings results on Friday, August, 11th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.06 by $0.21. The business earned $6.98 million during the quarter. Orgenesis had a negative trailing twelve-month return on equity of 107.27% and a negative net margin of 91.25%.

Who are Orgenesis' major shareholders?

Orgenesis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Orgenesis?

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Orgenesis have any subsidiaries?
The following companies are subsidiares of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.
Read More
This page (NASDAQ:ORGS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners